Moderna is creating a new category of transformative medicines based on messenger RNA, or mRNA. The company's pipeline includes development candidates for mRNA-based vaccines and therapies for use in various therapeutic areas comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
  • TickerMRNA
  • ISINUS60770K1079
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Bruno Cavalier ...
  • Pierre Tegner

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/12/2020

The short-term effect of the halted air traffic recovery is a (minor) delay in inventory reduction and the production rate ramp-up. However, we think that the current production rates provide a solid floor reinforced by a stabilised delivery skyline and robust assets (China, ECAs, aircraft retirements, etc.). Buy rating reiterated with a target price lowered to € 89 vs € 92. See the report published today - ...

Bruno Cavalier ...
  • Pierre Tegner

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 12/10/2020

Le coup d’arrêt porté à la reprise du trafic aérien implique à court terme un décalage (mineur) dans le temps de la réduction des stocks et de la remontée des cadences. A contrario, nous estimons que les cadences actuelles offrent un plancher solide porté par une skyline de livraisons assainie et de solides atouts (Chine, ECAs, retraits…). Achat réitéré avec un OC ajusté à 89 € (vs 92 €). - ...

Martial Descoutures ...
  • Sebastien Malafosse

Moderna : Verdict in a few weeks

>A road show logically focused on COVID-19 - We organised last Friday a road show with Stéphane Bancel, CEO of Moderna. This presentation was an opportunity to review notably the state of development of its vaccine for COVID-19 currently in phase III but also on the resultant opportunities. Following this road show, we reiterate our Buy recommendation ahead of the first interim results, in addition to our target price of € 86. An ambitious phase III trial...

Martial Descoutures ...
  • Sebastien Malafosse

Moderna : Verdict dans quelques semaines

>Un RS orienté logiquement sur la COVID-19 - Nous organisions vendredi dernier un roadshow avec Stéphane Bancel, CEO de Moderna. Cette présentation a été l’opportunité de revenir notamment sur le développement actuel de son vaccin contre la COVID-19 actuellement en phase 3 mais aussi sur les opportunités qui en découlent. Suite à cette journée, nous réitérons notre recommandation Achat en amont des premiers résultats intermédiaires ainsi que notre OC de 86 $. §hp...

An increasingly favourable environment allows MODERNA to improve to Neutral

The independent financial analyst theScreener just upgraded the general evaluation of MODERNA (US), a company active in the Biotechnology industry. As regards its fundamental valuation, the title confirms its rating of 3 out of 4 stars while its market behaviour remains as risky. theScreener believes, however, that a more enabling environment allows the title to increase its general evaluation to Neutral. As of the analysis date October 9, 2020, the closing price was USD 73.00 and its expected value was estimated at USD 69.22.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

ullish Tape Despite Inconsistencies Despite the bulls still being in control, we have several ongoing concerns and we cannot rule out the potential for a pullback. Below we highlight developments that are inconsistent with a major bottom in equities that suggests the broad equity market is not yet out of the woods. · S&P 500 Short-Term Levels. We continue to respect the bullish tape, however the S&P 500 remains in the 2855-2900 resistance zone while forming a bearish rising wedge pattern. This pattern results in a breakdown roughly 70% of the time. Still, support at 2760 would need ...

Martial Descoutures ...
  • Sebastien Malafosse

Moderna : Verdict in a few weeks

>A road show logically focused on COVID-19 - We organised last Friday a road show with Stéphane Bancel, CEO of Moderna. This presentation was an opportunity to review notably the state of development of its vaccine for COVID-19 currently in phase III but also on the resultant opportunities. Following this road show, we reiterate our Buy recommendation ahead of the first interim results, in addition to our target price of € 86. An ambitious phase III trial...

Martial Descoutures ...
  • Sebastien Malafosse

Moderna : Verdict dans quelques semaines

>Un RS orienté logiquement sur la COVID-19 - Nous organisions vendredi dernier un roadshow avec Stéphane Bancel, CEO de Moderna. Cette présentation a été l’opportunité de revenir notamment sur le développement actuel de son vaccin contre la COVID-19 actuellement en phase 3 mais aussi sur les opportunités qui en découlent. Suite à cette journée, nous réitérons notre recommandation Achat en amont des premiers résultats intermédiaires ainsi que notre OC de 86 $. §hp...

Anis Zgaya ...
  • Bruno Cavalier
  • Emmanuel Matot
  • Fehmi Ben Naamane
  • Jean Sassus
  • Johanna Jourdain
  • Louis Boujard, CFA
  • Martial Descoutures
  • Oussema Denguir
  • Philippe Ourpatian
  • Sebastien Malafosse
  • Steven Gould
  • Syrine Kabboura
  • Thomas Renaud

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 18/09/2020

...

Anis Zgaya ...
  • Emmanuel Matot
  • Fehmi Ben Naamane
  • Jean Sassus
  • Johanna Jourdain
  • Louis Boujard, CFA
  • Martial Descoutures
  • Oussema Denguir
  • Philippe Ourpatian
  • Sebastien Malafosse
  • Steven Gould
  • Syrine Kabboura
  • Thomas Renaud

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 09/18/2020

...

Martial Descoutures ...
  • Oussema Denguir
  • Sebastien Malafosse

Moderna : Further good progress

>Good progress, new ambitions - This R&D day was an opportunity for a recap on the company’s entire portfolio, which is still just as comprehensive (23 candidate therapies under development, 14 in clinical trials including 1 in phase III, 3 in phase II and 18 in phase I or preclinical trials).Moderna took advantage of the opportunity to present the preliminary results of the phase II trial in CytoMegaloVirus. This is the most advanced asset after MRNA1273 in SARS...

Bruno Cavalier ...
  • Pierre Tegner

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/12/2020

The short-term effect of the halted air traffic recovery is a (minor) delay in inventory reduction and the production rate ramp-up. However, we think that the current production rates provide a solid floor reinforced by a stabilised delivery skyline and robust assets (China, ECAs, aircraft retirements, etc.). Buy rating reiterated with a target price lowered to € 89 vs € 92. See the report published today - ...

Bruno Cavalier ...
  • Pierre Tegner

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 12/10/2020

Le coup d’arrêt porté à la reprise du trafic aérien implique à court terme un décalage (mineur) dans le temps de la réduction des stocks et de la remontée des cadences. A contrario, nous estimons que les cadences actuelles offrent un plancher solide porté par une skyline de livraisons assainie et de solides atouts (Chine, ECAs, retraits…). Achat réitéré avec un OC ajusté à 89 € (vs 92 €). - ...

Alfred Glaser ...
  • Benoit Valleaux
  • Chaima Ferrandon
  • Delphine Brault
  • Florent Laroche-Joubert
  • Jean Danjou
  • Maissa Keskes
  • Martial Descoutures
  • Martin Marandon-Carlhian
  • Nadine El Ouni
  • Nour El Houda Hammami
  • Oussema Denguir
  • Sebastien Malafosse
  • Slim Bouasker
  • Stephane Houri
  • Sven Edelfelt
  • Virginie Rousseau

AXA : Dear clients, We are very pleased to officially announce a partnership agreement between our group and ABN AMRO in equity brokerage. In adding a new domestic market to its platform, ODDO BHF is looking to become your new key provider for research an

...

Alfred Glaser ...
  • Benoit Valleaux
  • Chaima Ferrandon
  • Delphine Brault
  • Florent Laroche-Joubert
  • Maissa Keskes
  • Martial Descoutures
  • Martin Marandon-Carlhian
  • Nadine El Ouni
  • Nour El Houda Hammami
  • Oussema Denguir
  • Sebastien Malafosse
  • Slim Bouasker
  • Stephane Houri
  • Sven Edelfelt
  • Virginie Rousseau

AXA : OChers clients, Nous sommes très heureux de vous annoncer l’officialisation d’un accord de partenariat entre notre Groupe et ABN AMRO dans les métiers de l’intermédiation actions. En ajoutant un nouveau marché domestique à sa plateforme, ODDO BHF so

...

Bruno Cavalier ...
  • Louis Boujard, CFA
  • Philippe Ourpatian
  • Sylvain Goyon, CFA

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 07/27/2020

After years of unrealised €/$ bullish forecasts the single currency is finally on an upward trajectory. This change of course reflects a radical shift in the perception of the political risk associated with the European Union. The starting point for the rise (17 May) corresponds, moreover to the Franco-German announcement of the stimulus plan project. The European agreement of 21 July to begin the implementation process argues in favour, in a context of an upturn in PMIs, in favour of...

An increasingly favourable environment allows MODERNA to improve to Neutral

The independent financial analyst theScreener just upgraded the general evaluation of MODERNA (US), a company active in the Biotechnology industry. As regards its fundamental valuation, the title confirms its rating of 3 out of 4 stars while its market behaviour remains as risky. theScreener believes, however, that a more enabling environment allows the title to increase its general evaluation to Neutral. As of the analysis date October 9, 2020, the closing price was USD 73.00 and its expected value was estimated at USD 69.22.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch